Yes. In that particular case of cystinosis, I can speak confidently about it, because once that drug from the other company—the more expensive drug—became approved and was working its way through the negotiation process, I had a lot of cystinosis patients reach out to me. They said that they didn't want to lose access to the cheaper drug, that it worked for them and they didn't want to have to move over, and they asked what I could do.
I actually met with Health Canada. I met with the special access program director and said that I felt there was a unique role I could play in this, and that I would like to visit the company that was making that cheaper drug and do what I could to see if they would apply to Health Canada for standing, and then they could go through the reimbursement negotiations as well. That has taken place.
I met with that company and said that if they believed their drug was of value for patients in need, if they were a company that believed patients come first, would they please step forward and apply to Health Canada. They've done that. It's working its way through the system. At some point, whether they get a priority review or not, we should see that second drug approved. Then we'll have a very expensive drug on the market and one that's not as expensive, both of them doing the same thing.